Oligomerix has advanced its lead small molecule tau self-association inhibitor, known as OLX-07010, into first-in-human phase 1a clinical trials. This achievement is the result of a focus on the tau target for more than 16 years, enhancing our understanding of the role that tau plays in AD and other tauopathies such as PSP. Oligomerix is actively developing OLX-07010 for both Alzheimer’s Disease and PSP.
